natgillin/translations-raw huggingface dataset:
a conventional antimicrobial agent, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier. 
konvencionalno antimikrobno sredstvo, pri čemu je svaka od komponenata (A) i (B) formulirana u smjesi sa farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem.
A combination product according to Claim 18, wherein the conventional antimicrobial agent is co-amoxiclav, azithromycin, telithromycin, linezolid, daptomycin, levofloxacin, or moxifloxacin. 
Kombinirani proizvod prema zahtjevu 18, naznačen time da konvencionalno antimikrobno sredstvo je ko-amoksiklav, azitromicin, telitromicin, linezolid, daptomicin, levofloksacin, ili moksifloksacin.
a pharmaceutical formulation including a conventional antimicrobial agent, as defined in any one of Claims 17 to 19, or a pharmaceutically- acceptable salt and/or solvate thereof, in admixture with a pharmaceutically- acceptable adjuvant, diluent or carrier, which components (I) and (II) are each provided in a form that is suitable for administration in conjunction with the other. 
farmaceutsku formulaciju koja uključuje konvencionalno antimikrobno sredstvo, kako je definirano u bilo kojem od zahtjeva 17 do 19, ili njihovu farmaceutski prihvatljivu sol i/ili solvat, u smjesi sa farmaceutski prihvatljivim pomoćnim sredstvom, razrjeđivačem ili nosačem, te su navedene komponente (I) i (II) svaka predviđene u obliku koji je pogodan za davanje u kombinaciji s drugom.
The fusion protein for use according to claim 1, wherein the portion of said fusion protein that is C-terminal to said MTS consists of said functional component of an enzyme. 
Fuzijski protein za uporabu u skladu s patentnim zahtjevom 1, pri čemu se dio navedenog fuzijskog proteina koji je C-terminalan prema navedenom MTS sastoji od navedene funkcijske komponente enzima.
The fusion protein for use according to claim 2 wherein there are no residues heterologous to the enzyme present C-terminal to the MTS and cleavage of the said MTS generates an enzyme with the native sequence, which is readily integrated into a conformationally-sensitive multi-component enzyme complex. 
Fuzijski protein za uporabu u skladu s patentnim zahtjevom 2 pri čemu nema ostataka heterolognih enzimu prisutnom C-terminalno prema MTS i cijepanje navedenog MTS stvara enzim s nativnim slijedom, koji se odmah integrira u konformacijski osjetljiv višekomponentni enzimski kompleks.
The fusion protein for use of claim 1 or 2, wherein said enzyme is Lipoamide Dehydrogenase (LAD). 
Fuzijski protein za uporabu iz patentnog zahtjeva 1 ili 2, pri čemu je navedeni enzim lipoamid dehidrogenaza (LAD).
The fusion protein for use of claim 1 or 2, wherein said multi-component enzyme complex is selected from the group consisting of pyruvate dehydrogenase complex (PDHC), [alpha]-ketoglutarate dehydrogenase complex (KGDHC), and branched-chain keto-acid dehydrogenase complex (BCKDHC). 
Fuzijski protein za uporabu iz patentnog zahtjeva 1 ili 2, pri čemu je navedeni višekomponentni enzimski kompleks odabran iz grupe koja se sastoji od kompleksa piruvat dehidrogenaze (PDHC), kompleksa [alfa]-ketoglutarat dehidrogenaze (KGDHC) i kompleksa ketokisele dehidrogenaze razgranatih lanaca (BCKDHC).
The fusion protein for use as claimed in any one of claims 1 to 7 wherein said mitochondrial disorder is caused by a missense mutation in said enzyme. 
Fuzijski protein za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je navedeni mitohondrijski poremećaj uzrokovan besmislenom mutacijom u navedenom enzimu.
The fusion protein for use as claimed in any one of claims 1 to 7 wherein said mitochondrial disorder is selected from the group consisting of LAD deficiency and isolated Complex I deficiency. 
Fuzijski protein za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je navedeni mitohondrijski poremećaj odabran iz grupe koja se sastoji od deficijencije LAD i izolirane deficijencije kompleksa I.
The fusion protein for use as claimed in any one of claims 1 to 7 wherein said mitochondrial disorder is a neurodegenerative disease. 
Fuzijski protein za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je navedeni mitohondrijski poremećaj neurodegenerativna bolest.
The fusion protein for use as claimed in any one of claims 1 to 7 wherein said mitochondrial disorder is selected from the group consisting of encephalopathy and liver failure that is accompanied by stormy lactic acidosis, hyperammonemia and coagulopathy, Alpers Disease, Barth syndrome, Beta-oxidation Defects, Carnitine-Acyl-Carnitine Deficiency, Carnitine Deficiency, Co-Enzyme Q10 Deficiency, Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, Complex V Deficiency, COX Deficiency, CPEO, KSS, LCHAD, Leigh Disease or Syndrome, LHON, LIC (Lethal Infantile Cardiomyopathy), Luft Disease, MELAS, MERRF, Mitochondrial Cytopathy, Mitochondrial Myopathy, MNGIE, NARP, and Pyruvate Dehydrogenase Deficiency. 
Fuzijski protein za uporabu iz bilo kojeg od patentnih zahtjeva 1 do 7 pri čemu je navedeni mitohondrijski poremećaj odabran iz grupe koja se sastoji od encefalopatije i zatajenja jetre koje je praćeno burnom laktatnom acidozom, hiperamonijemijom i koagulopatijom, Alperove bolesti, sindroma Barth, nedostatka u beta-oksidaciji, nedostatka karnitin-acilkarnitina, nedostatka karnitina, nedostatka koenzima Q10, nedostatka kompleksa I, nedostatka kompleksa II, nedostatka kompleksa III, nedostatka kompleksa IV, nedostatka kompleksa V, nedostatka COX, CPEO, KSS, LCHAD, Leigh bolesti ili sindroma, LHON, LIC (letalne novorođenačke kardiomiopatije), Luftove bolesti, MELAS, MERRF, mitohondrijske citopatije, mitohondrijske miopatije, MNGIE, NARP i nedostatka piruvat dehidrogenaze.
J is a group A-[(CH2)n-O]r- in para position with respect to the ethylamino chain wherein: 
J je skupina A-[(CH2)n-O]r- na položaju para u odnosu na lanac etilamino, gdje:
A is phenyl substituted with a fluoro group; 
A je fenil supstituiran s fluorom kao skupinom;
is hydrogen; is hydrogen; (C1-C4)alkyl; cyclopropylmethyl; benzyl; or heterocyclylmethyl wherein the heterocyclyl group is selected from furanyl, tetrahydrofuranyl, and pyridinyl optionally substituted with a methoxy group; 
je vodik; je vodik; (C1-C4)alkil; ciklopropilmetil; benzil; ili heterociklilmetil, gdje se heterociklilnu skupinu bira između furanila, tetrahidrofuranila i piridinila izborno supstituiranog s metoksi skupinom;
is hydrogen; (C1-C4)alkyl optionally substituted with a group selected from amino, dimethylamino, and pyrrolidinyl wherein the pyrrolidinyl is optionally substituted with a methyl group; or 
je vodik; (C1-C4)alkil izborno supstituiran sa skupinom koju se bira između amino, dimetilamino i pirolidinila, gdje je pirolidinil izborno supstituiran s metilnom skupinom; ili
and R4 taken together with the adjacent nitrogen atom form a pyrrolidinyl or morpholinyl ring; or 
i R4, uzeti zajedno sa susjednim atomom dušika, tvore pirolidinilni ili morfolinilni prsten; ili
A compound of claim 1, group (b) wherein: 
Spoj u skladu s patentnim zahtjevom 1, skupina (b), naznačen time što:
A compound of any of claims of 1 to 7 for use as a medicament active as calcium and/or sodium channel modulator against disorders caused by dysfunctions of voltage gated calcium and/or sodium channels, such as neuropathic pain, chronic pain, acute pain, headaches, neurological conditions, cognitive and psychiatric disorders such as bipolar disorders, psychosis, anxiety and addiction, inflammatory processes affecting any body systems, disorders of the gastrointestinal tract, disorders of the genito-urinary tract, ophthalmic diseases, liver diseases, cardiovascular disorders and neurodegenerative disorders. 
Spoj u skladu s bilo kojim od patentnih zahtjeva od 1 do 7, naznačen time što je namijenjen upotrebi kao medikament aktivan kao modulator kalcijskih i/ili natrijskih kanala protiv poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput neuropatske boli, kronične boli, akutne boli, glavobolja, neuroloških stanja, kognitivni i psihijatrijskih poremećaja, poput bipolarnih poremećaja, psihoze, anksioznosti i ovisnosti, upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih poremećaja i neurodegenerativnih poremećaja.
A compound of any of claims 1 to 7 for use as a medicament for the treatment of neurological conditions such as epilepsy. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje neuroloških stanja, poput epilepsije.
A compound of any of claims 1 to 7 for use as a medicament for the treatment of cognitive and/or psychiatric disorders. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje kognitivnih i/ili psihijatrijskih poremećaja.
A compound as in any claims 1 to 7 for use as a medicament for the treatment of disorders caused by dysfunctions of voltage gated calcium and/or sodium channels such as inflammatory processes affecting any body systems, the disorders of the gastrointestinal tract, the disorders of the genito-urinary tract, the ophthalmic diseases, the liver diseases, the cardiovascular and/or neurodegenerative disorders. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što je namijenjen upotrebi kao medikament za liječenje poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih i/ili neurodegenerativnih poremećaja.
A compound of any of claims 1 to 7 for use as a medicament active as calcium and/or sodium channel modulator against disorders caused by dysfunctions of voltage gated calcium and/or sodium channels, such as neuropathic pain, chronic pain, acute pain, headaches, neurological conditions, cognitive and psychiatric disorders such as bipolar disorders, psychosis, anxiety and addiction, inflammatory processes affecting any body systems, disorders of the gastrointestinal tract, disorders of the genito-urinary tract, ophthalmic diseases, liver diseases, cardiovascular disorders and neurodegenerative disorders characterized in that the dosage of said compound which is effective in the treatment of a patient suffering of the affections caused by dysfunctions of voltage gated calcium and/or sodium channels does not exhibit any MAO inhibitory activity or exhibit a significantly reduced MAO inhibitory activity. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, namijenjen upotrebi kao medikament aktivan kao modulator kalcijskih i/ili natrijskih kanala protiv poremećaja uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala, poput neuropatske boli, kronične boli, akutne boli, glavobolja, neuroloških stanja, kognitivni i psihijatrijskih poremećaja, poput bipolarnih poremećaja, psihoze, anksioznosti i ovisnosti, upalnih procesa koji pogađaju bilo koji od tjelesnih sustava, poremećaja gastrointestinalnog sustava, poremećaja genitourinarnog sustava, bolesti očiju, bolesti jetre, kardiovaskularnih poremećaja i neurodegenerativnih poremećaja, naznačen time što doza navedenog spoja djelotvorna u liječenju pacijenta koji boluje od bolesti uzrokovanih disfunkcijama naponskih kalcijskih i/ili natrijskih kanala ne pokazuje bilo koju aktivnost inhibiranja MAO ili pokazuje znatno smanjenu aktivnost inhibiranja MAO.
A pharmaceutical composition containing a compound of the any of claims 1 to 7 as active ingredient together with a pharmaceutically acceptable excipient. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7 kao aktivni sastojak, uz farmaceutski prihvatljivu pomoćnu tvar.
perform uplink timing alignment based on the synchronous timing deviation information, in case that, in an uplink asynchronous status, the synchronous timing deviation information is included in the random access response (S02); 
provodi usklađivanje vremena uzlazne veze na temelju informacije o odstupanju sinkronog vremena, u slučaju da je, kod asinkronog statusa uzlazne veze, informacija o odstupanju sinkronog vremena uključena u odgovor sa slučajnim pristupom (S02);
A processing method executed by a mobile station device (50) which manages an uplink synchronous status by using a timer so that the uplink synchronous status is sustained until the timer expires after the timer is reset on receiving synchronous timing deviation information transmitted and calculated based on reception timing of a random access preamble by a base station device (10); wherein the processing method comprises: 
Postupak obrade koji se izvršava pomoću uređaja mobilne stanice (50) koji upravlja sinkronim statusom uzlazne veze korištenjem brojača vremena tako da se sinkroni status uzlazne veze održava sve do isteka brojača vremena nakon što se brojač vremena resetira kod prijema informacije o odstupanju sinkronog vremena koje se odašilje i izračunava na temelju primitka vremenskog rasporeda preambule slučajnog pristupa pomoću uređaja bazne stanice (10);
transmitting a random access preamble (S01) to the base station device (10); 
pri čemu postupak obrade obuhvaća: odašiljanje preambule slučajnog pristupa (S01) do uređaja bazne stanice (10);
culturing a modified microorganism in an appropriate culture medium comprising a source of carbon and a source of sulfur, wherein the expression of the methionine repressor encoded by the metJ gene is attenuated in said modified microorganism, and 
kultiviranje modificiranog mikroorganizma u odgovarajućem mediju za kulturu koji sadrži izvor ugljika i izvor sumpora, pri čemu je ekspresija metioninskog represora kojeg kodira metJ gen smanjena u rečenom modificiranom mikroorganizmu, te
recovering methionine from the culture medium, wherein compared to a non-modified method, the method has been modified to present an increased methionine/ carbon source yield by limiting growth and biomass production of the modified microorganism, by limiting or starving the microorganism for phosphate in the culture medium. 
izolacija metionina iz medija za kulturu, gdje je u usporedbi s nemodificiranom metodom, metoda modificirana tako da je kod modificiranog mikroorganizma povećan izvor metionina/ugljika ograničavanjem rasta i produkcije biomase modificiranog mikroorganizma, a ograničavanjem ili uskraćivanjem fosfata mikroorganzimu u mediju za kulturu.
The method of claim 1 to 9 wherein the carbon source is glucose or sucrose. 
Metoda iz patentnih zahtjeva 1 do 9, naznačena time da u mediju za kulturu izvor ugljika jest saharoza.
The method of claims 1 to 10 comprising a step of transformation of N-acetyl-methionine into methionine by deacylation, before methionine is recovered. 
Metoda iz patentnih zahtjeva 1 do 10, naznačena time da prije izoliranja metionina obuhvaća korak pretvorbe N-acetilmetionina u metionin deaciliranjem.
A solid preparation consisting of a layer containing pioglitazone or a salt thereof and a layer containing glimepiride and a polyoxyethylene sorbitan fatty acid ester including Polysorbate 20, Polysorbate 40, Polysorbate 60, Polysorbate 65 and Polysorbate 80 or a mixture of two or more of said polyoxyethylene sorbitan fatty acid esters. 
Kruti pripravak, naznačen time, da obuhvaća jedan sloj koji sadrži pioglitazon ili njegovu sol i jedan sloj koji sadrži glimepirid i ester masne kiseline polioksietilen-sorbitana, koji uključuje Polysorbat 20, Polysorbat 40, Polysorbat 60, Polysorbat 65 i Polysorbat 80 ili mješavinu od dva ili više navedenih estera masne kiseline polioksietilen-sorbitana.
The solid preparation according to claim 1, wherein the polyoxyethylene sorbitan fatty acid ester is Polysorbate 80. 
Kruti pripravak prema zahtjevu 1, naznačen time, da ester masne kiseline polioksietilen-sorbitana je Polysorbat 80.
is a partially or fully saturated or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, the ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, the heteroatoms selected from O, N, or S, wherein 0, 1, 2 or 3 atoms of each ring is optionally substituted independently with 1-5 substituents of R15; is H, halo, haloalkyl, haloalkoxyl, oxo, CN, OH, SH, NO2. 
je djelomično ili potpuno zasićeni ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, heteroatomi se izabiru između O, N, ili S, gdje je 0, 1, 2 ili 3 atoma svakog prstena po izboru supstituirano nezavisno s 1-5 supstituenta R15;
alternatively, either of R7 and R8 taken together with the carbon atoms to which they are attached form a partially or fully unsaturated 5- or 6-membered ring of carbon atoms optionally including 1-3 heteroatoms selected from O, N, or S, and the ring optionally substituted independently with 1-4 substituents of R13, R14 or R15; and each of R10, R11 and R12, independently, is H, halo, haloalkyl, CN, NO2, NH2, OH, methyl, methoxyl, ethyl, ethoxyl, propyl, propoxyl, isopropyl, cyclopropyl, butyl, isobutyl, tert-butyl, methylamine, dimethylamine, ethylamine, diethylamine, propylamine, isopropylamine, dipropylamine or diisopropylamine. 
alternativno, bilo koji od R7 i R8 uzet zajedno s atomima ugljika na koje su spojeni formira djelomično ili potpuno zasićeni 5- ili 6-eročlani prsten ugljikovih atoma koji po izboru obuhvaća 1-3 heteroatoma izabrana između O, N, ili S, i prsten je po izboru supstituiran nezavisno s 1-4 supstituenta od R13, R14 ili R15; i svaki od R10, R11 i R12, nezavisno, je H, halo, haloalkil, CN, NO2, NH2, OH, metil, metoksil, etil, etoksil, propil, propoksil, izopropil, ciklopropil, butil, izobutil, tert-butil, metilamin, dimetilamin, etilamin, dietilamin, propilamin, izopropilamin, dipropilamin ili diizopropilamin.
A process for preparing a compound of claims 1 or 6, the process comprising the step of reacting a compound of Formula A with a compound of Formula B wherein B1, B2, B3, B4, C1, D1, D2, L1, R1, R2, R3 and R4 of the compound of formula A and A1, A2 and R6, R7 and R8 of the compound of formula B are as defined in claims 1 or 6, and X is a halogen, to prepare the compound of Formula II. 
Postupak za pripremu spoja prema zahtjevima 1 ili 6, postupak obuhvaća korak reakcije spoja Formule A [image] sa spojem Formule B [image] gdje su B1, B2, B3, B4, C1, D1, D2, L1, R1, R2, R3 i R4 u spoju formule A te A1, A2 i R6, R7 i R8 u spoju formule B kako su definirani u zahtjevima 1 ili 6, i X je halogen, radi pripreme spoja Formule II.
is a partially or fully saturated or fully unsaturated 5-8 membered monocyclic, 6-12 membered bicyclic, or 7-14 membered tricyclic ring system, the ring system formed of carbon atoms optionally including 1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9 heteroatoms if tricyclic, the heteroatoms selected from O, N, or S, wherein 0, 1, 2 or 3 atoms of each ring is optionally substituted independently with 1-3 substituents of R15; 
je djelomično ili potpuno zasićeni ili potpuno nezasićeni 5-8-eročlani monociklički, 6-12-eročlani biciklički, ili 7-14-eročlani triciklički prstenasti sustav, prstenasti sustav formiran od ugljikovih atoma po izboru obuhvaća 1-3 heteroatoma ako je monociklički, 1-6 heteroatoma ako je biciklički, ili 1-9 heteroatoma ako je triciklički, heteroatomi se izabiru između O, N, ili S, gdje je 0, 1, 2 ili 3 atoma svakog prstena po izboru supstituirano nezavisno s 1-3 supstituenta R15;
A process for preparing a compound of claim 9, the process comprising the step of reacting a compound of Formula A' with a compound of Formula B wherein B1, B2, B3, B4, C1, L1, R1, R2, R3 and R4 of the compound of formula A' and A1, A2 and R6, R7 and R8 of the compound of formula B are as defined in claim 9, and X is a halogen, to prepare the compound of Formula III. 
Postupak za pripremu spoja prema zahtjevu 9, postupak obuhvaća korak reakcije spoja Formule A’ [image] sa spojem Formule B [image] gdje su B1, B2, B3, B4, C1, L1, R1, R2, R3 i R4 u spoju formule A' te A1, A2 i R6, R7 i R8 u spoju formule B kako su definirani u zahtjevu 9, i X je halogen, radi pripreme spoja Formule III.
A medicament comprising an effective dosage amount of a compound according to any of Claims 1-15 and a pharmaceutically acceptable carrier. 
Lijek koji sadrži učinkovitu dozirnu količinu spoja prema bilo kojem od zahtjeva 1-15 i farmaceutski prikladan nosač.
A compound according to any of claims 1-15 for use in reducing the size of a solid tumor or for use in the treatment of cancer, a hematological tumor or cell proliferation disorder in a subject. 
Spoj prema bilo kojem od zahtjeva 1-15 za uporabu u smanjenju veličine solidnog tumora ili za uporabu u liječenju raka, hematološkog tumora ili poremećaja stanične proliferacije u subjekta.
Use of a compound according to any of claims 1-7, 9, 11-15 for the preparation of a medicament for reducing the size of a solid tumor or for use in the treatment of cancer, a hematological tumor or cell proliferation disorder in a subject. 
Uporaba spoja prema bilo kojem od zahtjeva 1-7, 9, 11-15 za pripremu lijeka za smanjenje veličine solidnog tumora ili za uporabu u liječenju raka, hematološkog tumora ili poremećaja stanične proliferacije u subjekta.
A pharmaceutically acceptable salt form of the compound of claim 21. 
Farmaceutski prikladan oblik soli spoja prema zahtjevu 21.
A pharmaceutical composition comprising the compound of claim 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 
Farmaceutski pripravak koji sadrži spoj prema zahtjevu 21, ili njegovu farmaceutski prikladnu sol, i farmaceutski prikladnu pomoćnu tvar.
The compound according to any of claims 21-23 for use in the treatment of one or more cancers selected from bladder cancer, breast cancer, colon cancer, kidney cancer, liver cancer, lung cancer, esophagial cancer, gall-bladder cancer, ovarian cancer, pancreatic cancer, stomach cancer, cervical cancer, thyroid cancer, prostate cancer and skin cancer. 
Spoj prema bilo kojem od zahtjeva 21-23 za uporabu u liječenju jednog raka ili više njih izabranih između raka mjehura, raka dojke, raka kolona, raka bubrega, raka jetre, raka pluća, raka jednjaka, raka žučnog mjehura, raka jajnika, raka gušterače, raka želuca, raka cerviksa, raka štitnjače, raka prostate i raka kože.
A medicament comprising an effective dosage amount of a compound of any of claims 1-7, 12, 14 and 15 having the structure: or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. 
Lijek koji sadrži učinkovitu dozirnu količinu spoja prema bilo kojem od zahtjeva 1-7, 12, 14 i 15 koji ima strukturu: [image] ili njegovu farmaceutski prikladnu sol, i farmaceutski prikladan nosač.
A compound having the structure: or a pharmaceutically acceptable salt thereof, for use according to claim 29 in the treatment of B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma and non-Hodgkin's lymphoma. 
Spoj koji ima strukturu: [image] ili njegova farmaceutski prikladna sol, za uporabu prema zahtjevu 29 u liječenju B-staničnog limfoma, T-staničnog limfoma, Hodgkinovog limfoma i ne-Hodgkinovog limfoma.
The compound according to claim 2, wherein R2 represents a C1-10 alkoxy group which can be substituted by one or more substituents selected from a halogen atom, a C1-10 alkoxy group, and a C3-7 cycloalkyl group. 
Spoj prema zahtjevu 2, naznačen time, da R2 predstavlja C1-10 alkoksi-skupinu koja može biti supstituirana s jednim ili više supstituenata odabranih od atoma halogena, C1-10 alkoksi-skupine i C3-7 cikloalkil-skupine.